Lacosamide Accord

Lacosamide, the active ingredient in Lacosamide Accord, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the adjunctive treatment of partial‑onset seizures in patients with epilepsy. It is formulated for systemic absorption and is marketed across the European Union.

GNH USA supplies Lacosamide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Lacosamide is used in the management of epilepsy, specifically targeting focal seizure activity. - Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic therapy. - Focal epilepsy: Improves seizure control as adjunctive treatment in patients with refractory focal seizures. - Adjunctive therapy for refractory seizures: Provides additional seizure reduction in individuals not adequately controlled by other medications.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache - Diplopia - Blurred vision

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., atrial fibrillation, PR interval prolongation) - Suicidal thoughts or behavior - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hypersensitivity reactions (e.g., angioedema, anaphylaxis) - Rhabdomyolysis - Hepatic enzyme elevations

When prescribing lacosamide, clinicians should consider several safety precautions to minimize risk. - Cardiac assessment: Obtain baseline ECG to evaluate PR interval and cardiac conduction. - Suicidality monitoring: Observe patients for signs of depression or suicidal ideation during therapy. - Renal impairment: Adjust dose in patients with moderate to severe renal dysfunction. - Hepatic impairment: Use caution and consider dose reduction in patients with liver disease. - Discontinuation: Do not stop abruptly; taper the dose to avoid seizure exacerbation. - Store at room temperature: Keep in the original container, protect from moisture and excessive heat.

Lacosamide can interact with other medicines that affect its metabolism or cardiac conduction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase lacosamide plasma concentrations. - Concomitant drugs that prolong PR interval (e.g., beta‑blockers, digoxin): May enhance cardiac conduction effects. - Monoamine oxidase inhibitors: Potential for additive CNS effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): May reduce lacosamide levels. - Alcohol: May increase central nervous system depression. - Other antiepileptic drugs: May require dose adjustments to maintain efficacy.